Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CCDC6
REST API REST API
Homo sapiens
CCDC6 is differentially expressed in 266 experiments: 108 organism parts: amygdala, liver, ... (106 more);, 144 disease states: normal, control, ... (142 more);, 77 cell types 373 cell lines 40 compound treatments and 73 other conditions.
Synonyms H4, TST1, TPC, PTC, D10S170
Orthologs Ccdc6 (Rattus norvegicus)   Ccdc6 (Mus musculus)   CCDC6 (Gallus gallus)   ccdc6b (Danio rerio)   ccdc6a (Danio rerio)   CCDC6 (Bos taurus)   CG6664 (Drosophila melanogaster)   ccdc6 (Xenopus laevis)   CCDC6 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytoskeleton, cytoplasm, SH3 domain binding, biological_process, structural constituent of cytoskeleton
InterPro Term DUF2046
Gene-Disease Assocation THYROID CARCINOMA, PAPILLARY
UniProt Accession Q16204
Search EB-eye ENSG00000108091
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-4717, ... (32 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
BT474
2
E-MTAB-62, E-MTAB-37
MOLT4
2
E-MTAB-37, E-MTAB-62
PC3
2
E-MEXP-2034, E-GEOD-5258
T84
2
E-MTAB-37, E-GEOD-1474
SW480
1
2
E-MEXP-1014, E-GEOD-18005, E-GEOD-2509
367 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-21668, E-MEXP-750, E-GEOD-360, E-GEOD-20677, ... (41 experiments)

Factor Value U/D Experiments
embryonic stem cell
1
2
E-MEXP-930, E-GEOD-26672, E-GEOD-2248
BDCA1+ dendritic cell
1
1
E-TABM-34
CD34+ hematopoietic progenitor cell
1
E-GEOD-19240
induced pluripotent stem cell
1
E-GEOD-18147
leydig cell
1
E-MTAB-25
n/a
1
E-MTAB-24
71 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1615, E-GEOD-15960, E-GEOD-2466, E-GEOD-20168, ... (49 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-20168
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
bladder carcinoma
2
E-TABM-147, E-MTAB-37
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
colon carcinoma
2
E-MTAB-37, E-MTAB-62
glioblastoma
2
E-GEOD-4290, E-GEOD-4412
138 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (26 experiments)

Factor Value U/D Experiments
none
4
7
E-MEXP-1601, E-TABM-868, E-GEOD-5099, E-GEOD-7400, E-GEOD-412, ... (11 experiments)
2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidines
1
E-GEOD-6932
PGE2
1
E-MEXP-1230
TGF
1
E-GEOD-15205
granulocyte-macrophage colony-stimulating factor
1
E-MEXP-2000
heregulin
1
E-GEOD-6462
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-2509, E-TABM-147, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-3494, E-GEOD-2466, E-TABM-321, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-TABM-127, E-GEOD-20540, E-MEXP-1446, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (30 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-2487, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-GEOD-22152, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.329 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM